Literature DB >> 19074524

Investigation of the in vitro metabolism of the analgesic flupirtine.

Karen Methling1, Przyemslaw Reszka, Michael Lalk, Oldrich Vrana, Eberhard Scheuch, Werner Siegmund, Bernd Terhaag, Patrick J Bednarski.   

Abstract

The in vitro metabolism of flupirtine, ethyl-N-[2-amino-6-(4-fluorophenylmethyl-amino)pyridine-3-yl]carbamate, a centrally acting analgesic with muscle tone-reducing activity, was studied. Two flupirtine metabolites were already known: the N-acetylated analog D13223 and 4-fluorohippuric acid. The structure of flupirtine suggested that redox chemistry may play a role in metabolism, and cyclic voltammetry studies showed that the drug undergoes facile and irreversible redox reactions. Thus, oxidative metabolism was investigated first. With CYP3A1-induced rat liver microsomes an 18% turnover of flupirtine and a 20 to 25% turnover of D13223 took place over 30 min, but less than 5% turnover of flupirtine was observed with all human liver microsomal preparations tested, evidence that cytochrome P450 does not contribute appreciably to the metabolism in humans. Likewise, no involvement of human monoamine oxidase (isoforms A and B) was found for either flupirtine or D13223. In contrast, flupirtine was an excellent substrate for both human myeloperoxidase and horse radish peroxidase (HRP). These enzymes produced detectable amounts of oxidation products. Incubations of flupirtine with HRP produced an oxidation product that could be trapped with glutathione, the resulting glutathione conjugate was characterized by mass spectrometry and NMR. Metabolism of D13223 by both peroxidases was also observed but to a much lesser extent. Porcine liver esterases cleave the carbamate group of flupirtine, and both human N-acetyltransferases 1 and 2 acetylated the hydrolysis product, presumably descarboethoxyflupirtine, with nearly equal efficiencies to yield D13223. Incubations of human liver microsomes with flupirtine or the metabolite D13223 together with UDP-glucuronic acid gave two isomeric N-glucuronides in both cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074524     DOI: 10.1124/dmd.108.024364

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

1.  Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.

Authors:  Werner Siegmund; Christiane Modess; Eberhard Scheuch; Karen Methling; Markus Keiser; Ali Nassif; Dieter Rosskopf; Patrick J Bednarski; Jürgen Borlak; Bernd Terhaag
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 2.  Flupirtine in pain management: pharmacological properties and clinical use.

Authors:  Jacques Devulder
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

3.  Carba Analogues of Flupirtine and Retigabine with Improved Oxidation Resistance and Reduced Risk of Quinoid Metabolite Formation.

Authors:  Konrad W Wurm; Frieda-Marie Bartz; Lukas Schulig; Anja Bodtke; Patrick J Bednarski; Andreas Link
Journal:  ChemMedChem       Date:  2022-07-07       Impact factor: 3.540

Review 4.  PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches.

Authors:  Jingheng Wang; Monicah Bwayi; Rebecca R Florke Gee; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-06-16       Impact factor: 4.481

5.  Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting.

Authors:  Nora Anderson; Juergen Borlak
Journal:  PLoS One       Date:  2011-10-11       Impact factor: 3.240

6.  Flupirtine: Clinical pharmacology.

Authors:  S Harish; K Bhuvana; Girish M Bengalorkar; Tn Kumar
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-04

Review 7.  Chemical modulation of Kv7 potassium channels.

Authors:  Matteo Borgini; Pravat Mondal; Ruiting Liu; Peter Wipf
Journal:  RSC Med Chem       Date:  2021-01-14

Review 8.  TAMH: A Useful In Vitro Model for Assessing Hepatotoxic Mechanisms.

Authors:  Madison Davis; Brendan D Stamper
Journal:  Biomed Res Int       Date:  2016-12-15       Impact factor: 3.411

9.  Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

Authors:  Valentina Peta; Chantal Tse; Hugo Perazzo; Mona Munteanu; Yen Ngo; An Ngo; Nittia Ramanujam; Lea Verglas; Maxime Mallet; Vlad Ratziu; Dominique Thabut; Marika Rudler; Vincent Thibault; Ina Schuppe-Koistinen; Dominique Bonnefont-Rousselot; Bernard Hainque; Françoise Imbert-Bismut; Michael Merz; Gerd Kullak-Ublick; Raul Andrade; Florian van Boemmel; Eckart Schott; Thierry Poynard
Journal:  PLoS One       Date:  2017-12-29       Impact factor: 3.240

10.  Bioequivalence study of two formulations of flupirtine maleate capsules in healthy male Chinese volunteers under fasting and fed conditions.

Authors:  Yanfang Liu; Hua Huo; Zhibo Zhao; Wenli Hu; Yujia Sun; Yunbiao Tang
Journal:  Drug Des Devel Ther       Date:  2017-12-01       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.